Teduglutide for the Treatment of Short Bowel Syndrome

Marcus Ferrone and James S Scolapio

Email to a Friend       Add to Cart           Continue Shopping

OBJECTIVE: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS).

DATA SOURCES: Clinical literature, including both primary sources and review articles, was accessed through a search of the MEDLINE databases (1980-March 2006). Key search terms included teduglutide, ALX-0600, glucagon-like peptide-2, short bowel syndrome, short gut, and intestinal adaptation. Clinical trial and drug data were supplied by the manufacturer, NPS Pharmaceuticals.

STUDY SELECTION AND DATA EXTRACTION: Review articles, abstracts, and clinical studies related to GLP-2 and its analog, teduglutide, were analyzed. An evaluation of the research exploring teduglutide for the management of SBS was conducted. Relevant information was then selected.

DATA SYNTHESIS: Research has revealed that administration of GLP-2 to patients following major small bowel resection improves intestinal adaptation and nutrient absorption. Teduglutide is an enzyme-resistant GLP-2 analog that shows promise in preventing intestinal injury, restoring mucosal integrity, and enhancing intestinal absorptive function.

CONCLUSIONS: Data from ongoing clinical trials indicate that teduglutide may have the ability to enhance intestinal absorptive capacity in patients with SBS. Further studies and the completion of Phase III trials are necessary to determine the appropriate dosage and length of treatment for patients with SBS to gain optimal therapeutic benefit from this drug.

Key Words: ALX-0600, glucagon-like peptide-2, short bowel syndrome, teduglutide.

Published Online, May 16, 2006. www.theannals.com, DOI 10.1345/aph.1G419

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-011-H01